Drug-induced pneumonitis in cancer patients treated with mTOR inhibitors: Management and insights into possible mechanisms

Expert Opinion on Drug Safety

Volumn 13, Issue 3, 2014, Pages 361-372

  Duran, Ignacio ^a   Goebell, Peter Jürgen ^b   Papazisis, Konstantinos ^c   Ravaud, Alain ^d   Weichhart, Thomas ^e   Rodriguez Portal, Jose Antonio ^a   Budde, Klemens ^f  

^a HOSPITAL UNIVERSITARIO VIRGEN DEL ROCÍO   (Spain)

^b UNIVERSITY HOSPITAL ERLANGEN   (Germany)

^c Euromedica General Clinic   (Greece)

^d UNIVERSITÉ DE BORDEAUX   (France)

^e MEDICAL UNIVERSITY OF VIENNA   (Austria)

^f CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

Author keywords

Drug induced pneumonitis; Mammalian target of rapamycin inhibitors; Renal cell carcinoma; Tuberous sclerosis complex

Indexed keywords

MAMMALIAN TARGET OF RAPAMYCIN INHIBITOR;

ADAPTIVE IMMUNITY; CANCER PATIENT; CHRONIC OBSTRUCTIVE LUNG DISEASE; CLINICAL TRIAL (TOPIC); COMPUTER ASSISTED TOMOGRAPHY; CORTICOSTEROID THERAPY; DRUG INDUCED DISEASE; FOLLOW UP; HEALTH CARE PERSONNEL; HUMAN; INNATE IMMUNITY; INTERSTITIAL LUNG DISEASE; LUNG FIBROSIS; LUNG FUNCTION TEST; MACROPHAGE; MEMORY T LYMPHOCYTE; MONOCYTE; PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); PNEUMONIA; QUALITY OF LIFE; RECEPTOR UPREGULATION; REVIEW;

ANTINEOPLASTIC AGENTS; HUMANS; NEOPLASMS; PNEUMONIA; TOR SERINE-THREONINE KINASES;

EID: 84896724265     PISSN: 14740338     EISSN: 1744764X     Source Type: Journal    
DOI: 10.1517/14740338.2014.888056     Document Type: Review

References (60)

1. Wander SA, Hennessy BT, Slingerland JM. Next-generation mTOR inhibitors in clinical oncology: How pathway complexity informs therapeutic strategy. J Clin Invest 2011;121:1231-41
2. Martelli AM, Chiarini F, Evangelisti C, et al. Two hits are better than one: Targeting both phosphatidylinositol 3-kinase and mammalian target of rapamycin as a therapeutic strategy for acute leukemia treatment. Oncotarget 2012;3:371-94
3. Hudes GR. Targeting mTOR in renal cell carcinoma. Cancer 2009;115(10 Suppl):2313-20
4. Sparks CA, Guertin DA. Targeting mTOR: Prospects for mTOR complex 2 inhibitors in cancer therapy. Oncogene 2010;29:3733-44
5. Zhou H, Luo Y, Huang S. Updates of mTOR inhibitors. Anticancer Agents Med Chem 2010;10:571-81
6. Oshiro N, Yoshino K, Hidayat S, et al. Dissociation of raptor from mTOR is a mechanism of rapamycin-induced inhibition of mTOR function. Genes Cells 2004;9:359-66
7. Torisel 30 mg concentrate and diluent for solution for infusion. Summary of product characteristics, last updated August 2013. Available from: Http:// www.emea.europa.eu/docs/enGB/ documentlibrary/EPAR- ProductInformation/human/ 000799/ WC500039912.pdf [Last accessed 20 September 2013]
8. Rapamune (sirolimus) oral solution and tablets. Prescribing information, revised December 2012. Available from: Http:// labeling.pfizer.com/showlabeling. aspx? id=139 [Last accessed 20 September 2013]
9. Halleck F, Duerr M, Waiser J, et al. An evaluation of sirolimus in renal transplantation. Expert Opin Drug Metab Toxicol 2012;8:1337-56
10. Afinitor (everolimus) tablets for oral administration. Prescribing information, revised August 2012. Available from: Http://www.pharma.us.novartis. com/ product/pi/pdf/afinitor.pdf [Last accessed 20 September 2013]
11. Afinitor 2.5 mg tablets. Summary of product characteristics, last updated September 2013. Available from: Http:// www.ema.europa.eu/docs/enGB/ documentlibrary/EPAR- ProductInformation/human/001038/ WC500022814.pdf [Last accessed 20 September 2013]
12. Keedy VL. Treating metastatic soft-tissue or bone sarcomas - potential role of ridaforolimus. Onco Targets Ther 2012;5:153-60
13. Baselga J, Campone M, Piccart M, et al. Everolimus in postmenopausal hormone-receptor-positive advanced breast cancer. N Engl J Med 2012;366:520-9
14. Smith SM, van Besien K, Karrison T, et al. Temsirolimus has activity in non-mantle cell non-Hodgkin's lymphoma subtypes: The University of Chicago phase II consortium. J Clin Oncol 2010;28:4740-6
15. Soria JC, Shepherd FA, Douillard JY, et al. Efficacy of everolimus (RAD001) in patients with advanced NSCLC previously treated with chemotherapy alone or with chemotherapy and EGFR inhibitors. Ann Oncol 2009;20:1674-81
16. Diaz-Padilla I, Duran I, Clarke BA, Oza AM. Biologic rationale and clinical activity of mTOR inhibitors in gynecological cancer. Cancer Treat Rev 2012;38:767-75
17. Wullschleger S, Loewith R, Hall MN. TOR signaling in growth and metabolism. Cell 2006;124:471-84
18. Eisen T, Sternberg CN, Robert C, et al. Targeted therapies for renal cell carcinoma: Review of adverse event management strategies. J Natl Cancer Inst 2012;104:93-113
19. Rodriguez-Pascual J, Cheng E, Maroto P, Duran I. Emergent toxicities associated with the use of mTOR inhibitors in patients with advanced renal carcinoma. Anticancer Drugs 2010;21:478-86
20. Aparicio G, Calvo MB, Medina V, et al. Comprehensive lung injury pathology induced by mTOR inhibitors. Clin Transl Oncol 2009;11:499-510
21. Barber NA, Ganti AK. Pulmonary toxicities from targeted therapies: A review. Target Oncol 2011;6:235-43
22. Borders EB, Bivona C, Medina PJ. Mammalian target of rapamycin: Biological function and target for novel anticancer agents. Am J Health Syst Pharm 2010;67:2095-106
23. Morelon E, Stern M, Kreis H. Interstitial pneumonitis associated with sirolimus therapy in renal-transplant recipients. N Engl J Med 2000;343:225-6
24. Pham PT, Pham PC, Danovitch GM, et al. Sirolimus-associated pulmonary toxicity. Transplantation 2004;77:1215-20
25. Atkins MB, Hidalgo M, Stadler WM, et al. Randomized phase II study of multiple dose levels of CCI-779, a novel mammalian target of rapamycin kinase inhibitor, in patients with advanced refractory renal cell carcinoma. J Clin Oncol 2004;22:909-18
26. Duran I, Siu LL, Oza AM, et al. Characterisation of the lung toxicity of the cell cycle inhibitor temsirolimus. Eur J Cancer 2006;42:1875-80
27. Albiges L, Chamming's F, Duclos B, et al. Incidence and management of mTOR inhibitor-associated pneumonitis in patients with metastatic renal cell carcinoma. Ann Oncol 2012;23:1943-53
28. Porta C, Osanto S, Ravaud A, et al. Management of adverse events associated with the use of everolimus in patients with advanced renal cell carcinoma. Eur J Cancer 2011;47:1287-98
29. White DA, Camus P, Endo M, et al. Noninfectious pneumonitis after everolimus therapy for advanced renal cell carcinoma. Am J Respir Crit Care Med 2010;182:396-403
30. Sa?emann MD, Haidinger M, Hecking M, et al. The multifunctional role of mTOR in innate immunity: Implications for transplant immunity. Am J Transplant 2009;9:2655-61
31. Brouard S, Puig-Pey I, Lozano JJ, et al. Comparative transcriptional and phenotypic peripheral blood analysis of kidney recipients under cyclosporin A or sirolimus monotherapy. Am J Transplant 2010;10:2604-14
32. Haidinger M, Poglitsch M, Geyeregger R, et al. A versatile role of mammalian target of rapamycin in human dendritic cell function and differentiation. J Immunol 2010;185:3919-31
33. Weichhart T, Costantino G, Poglitsch M, et al. The TSC-mTOR signaling pathway regulates the innate inflammatory response. Immunity 2008;29:565-77
34. Yoshida T, Mett I, Bhunia AK, et al. Rtp801, a suppressor of mTOR signaling, is an essential mediator of cigarette smoke-induced pulmonary injury and emphysema. Nat Med 2010;16:767-73
35. Fielhaber JA, Carroll SF, Dydensborg AB, et al. Inhibition of mammalian target of rapamycin augments lipopolysaccharide-induced lung injury and apoptosis. J Immunol 2012;188:4535-42
36. Weichhart T, Haidinger M, Katholnig K, et al. Inhibition of mTOR blocks the anti-inflammatory effects of glucocorticoids in myeloid immune cells. Blood 2011;117:4273-83
37. Powell JD, Pollizzi KN, Heikamp EB, Horton MR. Regulation of immune responses by mTOR. Annu Rev Immunol 2012;30:39-68
38. Antoniou KM, Margaritopoulos GA, Soufla G, et al. Expression analysis of Akt and MAPK signaling pathways in lung tissue of patients with idiopathic pulmonary fibrosis (IPF). J Recept Signal Transduct Res 2010;30:262-9
39. Buron F, Malvezzi P, Villar E, et al. Profiling sirolimus-induced inflammatory syndrome: A prospective tricentric observational study. PLoS One 2013;8:e53078
40. David S, Ku?mpers P, Shin H, et al. Everolimus-associated interstitial pneumonitis in a patient with a heart transplant. Nephrol Dial Transplant 2007;22:3363-4
41. Weiner SM, Sellin L, Vonend O, et al. Pneumonitis associated with sirolimus: Clinical characteristics, risk factors and outcome - a single-centre experience and review of the literature. Nephrol Dial Transplant 2007;22:3631-7
42. Rehm B, Keller F, Mayer J, Stracke S. Resolution of sirolimus-induced pneumonitis after conversion to everolimus. Transplant Proc 2006;38:711-13
43. Ellard SL, Clemons M, Gelmon KA, et al. Randomized phase II study comparing two schedules of everolimus in patients with recurrent/metastatic breast cancer: NCIC Clinical Trials Group IND.163. J Clin Oncol 2009;27:4536-41
44. Cauley DH, Atkinson BJ, Ng CS, et al. Everolimus (E) and temsirolimus (T) associated pneumonitis (P) in patients with metastatic renal cell cancer (mRCC): A single-center experience. J Clin Oncol 2012;30(Suppl 5):abstract 401
45. Maroto JP, Hudes G, Dutcher JP, et al. Drug-related pneumonitis in patients with advanced renal cell carcinoma treated with temsirolimus. J Clin Oncol 2011;29:1750-6
46. Albiges L, Caramella C, Ferte C, et al. Interstitial pneumonitis during RAD-001 treatment: Incidence by blinded radiological analysis [abstract 7114]. Eur J Cancer Suppl 2009;7(Suppl 2):427
47. Amato RJ, Jac J, Giessinger S, et al. A phase 2 study with a daily regimen of the oral mTOR inhibitor RAD001 (everolimus) in patients with metastatic clear cell renal cell cancer. Cancer 2009;115:2438-46
48. Gru?nwald V, Karakiewicz PI, Bavbek SE, et al. An international expanded-access programme of everolimus: Addressing safety and efficacy in patients with metastatic renal cell carcinoma who progress after initial vascular endothelial growth factor receptortyrosine kinase inhibitor therapy. Eur J Cancer 2012;48:324-32
49. Cauley DH, Atkinson BJ, Corn PG, et al. Everolimus-associated pneumonitis (EAP) in metastatic renal cell cancer patients (mRCC): A single-center experience. J Clin Oncol 2011;29(Suppl):abstract 332
50. Motzer RJ, Escudier B, Oudard S, et al. Efficacy of everolimus in advanced renal cell carcinoma: A double-blind, randomised, placebo-controlled phase III trial. Lancet 2008;372:449-56
51. Franz DN, Belousova E, Sparagana S, et al. Efficacy and safety of everolimus for subependymal giant cell astrocytomas associated with tuberous sclerosis complex (EXIST-1): A multicentre, randomised, placebo-controlled phase 3 trial. Lancet 2013;381:125-32
52. Bissler JJ, Kingswood JC, Radzikowska E, et al. Everolimus for angiomyolipoma associated with tuberous sclerosis complex or sporadic lymphangioleiomyomatosis (EXIST-2): A multicentre, randomised, double-blind, placebo-controlled trial. Lancet 2013;381:817-24
53. Bellmunt J, Szczylik C, Feingold J, et al. Temsirolimus safety profile and management of toxic effects in patients with advanced renal cell carcinoma and poor prognostic features. Ann Oncol 2008;19:1387-92
54. Krueger DA, Care MM, Holland K, et al. Everolimus for subependymal giant-cell astrocytomas in tuberous sclerosis. N Engl J Med 2010;363:1801-11
55. Oberstein PE, Saif MW. Safety and efficacy of everolimus in adult patients with neuroendocrine tumors. Clin Med Insights Oncol 2012;6:41-51
56. Alexandru S, Ortiz A, Baldovi S, et al. Severe everolimus-associated pneumonitis in a renal transplant recipient. Nephrol Dial Transplant 2008;23:3353-5
57. Errasti P, Izquierdo D, Marti'n P, et al. Pneumonitis associated with mammalian target of rapamycin inhibitors in renal transplant recipients: A single-center experience. Transplant Proc 2010;42:3053-4
58. Bradley B, Branley HM, Egan JJ, et al. Interstitial lung disease guideline: The British Thoracic Society in collaboration with the Thoracic Society of Australia and New Zealand and the Irish Thoracic Society. Thorax 2008;63(Suppl 5):v1-v58
59. Di Lorenzo G, Porta C, Bellmunt J, et al. Toxicities of targeted therapy and their management in kidney cancer. Eur Urol 2011;59:526-40
60. NIH Common Terminology Criteria for Adverse Events (CTCAE) v. 4, last modified May 2010. Available from: Http://evs.nci.nih.gov/ftp1/CTCAE/About. html [Last accessed 20 September 2013]